Screening for Residual Disease in Pediatric Burkitt Lymphoma Using Consensus Primer Pools

Assessing molecular persistent or minimal residual disease (PD/MRD) in childhood Burkitt lymphoma (BL) is challenging because access to original tumor is usually needed to design patient-specific primers (PSPs). Because BL is characterized by rearranged immunoglobulin heavy chain (IgV(H)) genes, IgV...

Descripción completa

Detalles Bibliográficos
Autores principales: Agsalda, Melissa, Kusao, Ian, Troelstrup, David, Shiramizu, Bruce
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771857/
https://www.ncbi.nlm.nih.gov/pubmed/19890467
http://dx.doi.org/10.1155/2009/412163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771857/
https://www.ncbi.nlm.nih.gov/pubmed/19890467
http://dx.doi.org/10.1155/2009/412163

Ejemplares similares